Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

Singapore Clinical Trial: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More

FDA Grants Full Approval To Lilly's Inluriyo Plus Verzenio For ESR1-Mutated Breast Cancer

India, Sept. 18 -- Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antagonist, for... Read More

21 killed, 78 injured in Pakistan mosque blast near police compound

India, Sept. 18 -- At least 21 people were killed and 78 injured after an explosives-laden vehicle rammed into a mosque near a police compound in Kohat, Pakistan's Khyber Pakhtunkhwa province, during ... Read More

400 Indonesian Navy personnel set to crew KRI Sriwijaya

Jakarta, Sept. 18 -- The Indonesian Navy has prepared a 400-member crew to operate the newly acquired aircraft carrier that will be renamed KRI Sriwijaya following its official handover from Italy on ... Read More

Singapore Clinical Trial: A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety... Read More

Singapore Clinical Trial: A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety an... Read More

Singapore Clinical Trial: A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD... Read More

• ««
• «
• 3481
• 3482
• 3483
• 3484
• 3485
• 3486
• 3487
• 3488
• 3489
• 3490
• »
• »»